Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)
Phase 3Recruiting 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Pain
Conditions
Acute Pain
Trial Timeline
Feb 1, 2026 → Oct 1, 2026
NCT ID
NCT07225634About Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)
Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion) is a phase 3 stage product being developed by AFT Pharmaceuticals for Acute Pain. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225634. Target conditions include Acute Pain.
What happened to similar drugs?
20 of 20 similar drugs in Acute Pain were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07225634 | Phase 3 | Recruiting |
Competing Products
20 competing products in Acute Pain